secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2026-07-27T20:08:03+00:00
Accession:  0001193125-26-318069
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health Q2 2026 net loss narrows to $8.4M; provides FY 2026 revenue guidance $560-585M
--------------------------------------------------------------------------------

- Consolidated revenue $163.5M vs $156.8M YoY; operating loss improved to $7.0M from $60.0M.
- Net loss $8.4M ($0.01/share) vs $148.4M ($0.19/share) in Q2 2025.
- Diagnostics revenue $74.5M (down from $101.1M due to oncology asset sale to Labcorp); pharma product revenue $42.9M.
- Cash and equivalents $314.4M; $105.3M of stock repurchased under $200M program.
- FY 2026 total revenue guidance $560-585M; Q3 2026 revenue guidance $131-142M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000119312526318069/0001193125-26-318069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000119312526318069/opk-20260727.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-318069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer